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Abstract
SoxB1 sub-family of transcriptional regulators are expressed in progenitor (NP) cells throughout the neuroaxis and are
generally downregulated during neuronal differentiation. Gain- and loss-of-function studies indicate that Sox1, Sox2 and
Sox3 are key regulators of NP differentiation and that their roles in CNS development are largely redundant. Nevertheless,
mutation of each SoxB1 individually results in a different array of CNS defects, raising the possibility that SoxB1 proteins
have subtly different functions in NP cells. To explore the mechanism of SOXB1 functional redundancy, and to identify
genes that are most sensitive to loss of the Sox3 gene, we performed genome wide expression profiling of Sox3 null NP
cells. Nineteen genes with abnormal expression were identified, including the homeobox gene Dbx1. Analysis of Sox3 null
embryos revealed that Dbx1 was significantly reduced in the neural tube and developing brain and that SOX3 bound
directly to conserved elements associated with this gene in cultured NP cells and in vivo. These data define Dbx1 as a direct
SOX3 target gene whose expression, intriguingly, is not fully rescued by other SOXB1 transcription factors, suggesting that
there are inherent differences in SOXB1 protein activity.
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Introduction
SOX3 is a member of the SOX (Sry-related HMG box) family
of transcription factors, of which 20 members have been identified
in mammals. SOX genes generally have developmentally-regulated
expression and play important roles in cell specification, self-
renewal and differentiation in a broad range of embryonic
contexts [1]. Within the developing central nervous system
(CNS), Sox3, and the closely related genes Sox1 and Sox2 (which
together make up the SoxB1 subgroup), are expressed in
neuroprogenitor cells throughout the neuroaxis and are down
regulated upon differentiation [2,3]. Overexpression studies in
chick embryonic spinal cords and cultured murine neuroprogeni-
tor (NP) cells indicate that SOXB1 proteins function as inhibitors
of neurodifferentiation and that they have overlapping roles in this
process [2,4]. SOXB1 group functional redundancy is also
supported by loss-of-function studies in mammals. Sox3 null mice
exhibit specific CNS defects within the hippocampus, corpus
callosum and hypothalamus despite the widespread Sox3 expres-
sion in NP cells throughout the developing brain [5,6]. In addition,
humans with polyalanine tract expansion mutations in SOX3 have
a relatively mild phenotype that includes infundibular hypoplasia,
hypothamalic-pituitary axis dysfunction and incompletely pene-
trance of intellectual disability [7,8]. CNS-specific deletion of Sox2
or Sox1 in mice also results in regionally-restricted defects as
opposed to a general NP phenotype [9,10,11,12,13].
While these studies provide strong support for SOXB1
functional redundancy, the existence of congenital CNS defects
in Sox3, Sox2 and Sox1 single gene mutant mice also indicates that
there is a specific requirement for each SOXB1 factor in a
(relatively small) subpopulation of NP cells. This phenomenon can
be explained by at least three possibilities. Firstly, given that subtle
differences in Sox1, Sox2 and Sox3 gene expression have been
identified in the developing CNS [3,14,15], it is possible that some
NP cells express only one SOXB1 gene. Deletion of the single
expressing SoxB1 gene in these cells would likely cause a specific
developmental defect due to the complete absence of SOXB1
activity. However, while this is an attractive hypothesis, NP cells
expressing only one SOXB1 gene have not been definitively
identified. Furthermore, contrary to this possibility, structures that
express more than one SOXB1 gene can be defective in single
gene mutants. For example, development of the infundibulum is
abnormal in Sox3 null embryos despite expression of Sox2 in this
structure [5]. A second possibility is that SOXB1 proteins can bind
to and regulate the same set of target genes but that each factor
has a unique preference for specific targets over others due to their
inherent sequence-specific DNA binding activity. In this scenario,
deletion of a single SoxB1 gene would only affect the expression of
SOXB1 targets for which it has a uniquely high affinity. Consistent
with this idea, recent ChIP-seq analysis has revealed extensive
overlap between SOX2 and SOX3 binding sites in NP cells [4]. A
third possibility is that the SOXB1 proteins are functionally
identical and that changes in the dosage of SOXB1 protein, as a
whole, in an NP cell will alter the expression of some target genes.
A prediction of this hypothesis is that mutation of individual
SoxB1 genes would result in near identical or at least similar
phenotypes. However, on the contrary, the phenotypes of single
gene mutations are quite distinct and have few overlapping
features.
To explore the mechanism of SOXB1 functional redundancy,
and to identify genes that are most sensitive to loss of the Sox3
gene, we performed genome wide expression profiling of Sox3 null
NP cells. Nineteen genes with abnormal/delayed expression were
identified that included the homeobox gene Dbx1. In vivo analysis
of Sox3 null embryos revealed that Dbx1 was significantly reduced
in the neural tube and developing brain and that SOX3 bound
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directly to conserved elements associated with this gene in cultured
NP cells and in vivo. These data define Dbx1 as a direct SOX3
target gene whose expression, intriguingly, is not fully rescued by
other SOXB1 transcription factors, suggesting that there are
inherent differences in SOXB1 protein activity.
Methods
ES Cell Generation
Sox3 null embryonic stem cells were previously targeted as
described in (Hughes et al 2013). Sox3 null mice have been
published previously [5].
ES Cell Culture and Neurodifferentiation
R1 ES cells were maintained on irradiated MEFs in standard
conditions and neurodifferentiated as monolayers using N2B27 as
previously described [16].
Microarray and qRT-PCR
RNA from differentiated cells was extracted using a RNeasy
mini kit (Qiagen) and cDNA generated using a High Capacity
RNA-to-cDNA kit (ABI). Expression profiling was performed on
four wild type and four Sox3 null Day 4 samples using Affymetrix
GeneChip Mouse Gene 1.0 ST Arrays (full dataset available at
Gene Expression Omnibus: GSE53760). 2 way-ANOVA, using
batch as a factor, was used to identify the significantly regulated
genes. qRT-PCR validation was performed previously described
[17].
Immunohistochemistry
IHC was performed as described previously [3].
Chromatin Immunoprecipitation (Chip)
In vitro ChIP was performed as per [4] using 5 ug of SOX3 or
IgG antibodies, with Dynabeads blocked over night with 200 ug
BSA, 200 ug yeast tRNA and 200 ug glycogen. In vivo ChIP was
performed with wild type 10.5 dpc embryonic heads, disassociated
with scalpel blades and fixed for 10 minutes using the above
protocol. ChIP samples were analysed by qPCR (StepOne Plus,
Applied Biosystems) using Fast SYBR (Life Technologies). Signals
were considered positive when 2‘-[Ctsample (non-enriched region) -
Ctsample (peak region)] was .2 following normalisation to CtIgG
and CtInput of the corresponding qPCR run.
Ethics Statement
Animal experiments were approved by the University of
Adelaide Animal Ethics Committee (project number: S-2012-
242). All studies were conducted in accordance with the principles
Figure 1. Sox3 expression in neural progenitor differentiation. A: Time course of Sox3 gene expression levels by qRT-PCR throughout N2B27
differentiation (normalised to day 4 Sox3 expression, n = 3). B: IHC of SOX3 showing expression at days 2, 4 and 6 of neuronal differentiation. C: GFP
expressing cells sorted by FACS within Sox3 null N2B27 differentiated ES cells at days 2, 4 and 7. D: qRT-PCR of Sox1, Sox2, Sox2 and Pax6 expression at
day 4 of N2B27 differentiation (n$4). RQ: relative quantification normalised to b-actin.
doi:10.1371/journal.pone.0095356.g001
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of animal replacement and reduction and experimental refine-
ment.
Results
Sox3 Expression during In vitro Neural Progenitor
Differentiation
To begin to identify SOX3 target genes in NP cells, we utilised
the N2B27 culture system, which has previously been shown to
generate NP cells from ESC with high efficiency [16]. To
characterise Sox3 expression during N2B27 neuroinduction, we
performed qRT-PCR (Fig. 1A) and immunohistochemistry
analysis (Fig. 1B;[3]). At the mRNA level, Sox3 expression was
virtually undetectable in ESC (Day 0). Sox3 expression was
upregulated by Day 2, and increased further at Day 4 and Day 6.
Consistent with these data, weak expression of SOX3 protein was
evident in Day 2 cultures. By Day 4, robust expression of SOX3
was detected in most cells. At Day 6, robust expression of SOX3
could still be detected in most cells, although some cells
(particularly those at the periphery of colonies) had begun to
downregulate SOX3.
To investigate the impact of Sox3 deletion on NP differentiation,
we performed N2B27 neuroinduction using our previously-
generated Sox3 null ES cells that contain a GFP reporter knock-
in allele [17]. FACS analysis of Day 4 NP cultures revealed that
the majority (over 60%) of cells were GFP+, which is comparable
to the proportion of cells that are SOX3+ in the WT NP cultures
(Figure 1B,C). To determine whether the loss of Sox3 has a major
impact on induction of neural progenitors, expression of neural
progenitor markers (including other SoxB1 genes) was analysed by
qRT-PCR. No significant difference in Sox1, Sox2 or Pax6
expression was detected in samples utilized for microarray
analysis, at Day 4 (Fig. 1D). No change in expression of the other
SoxB1 subgroup members was also observed on Day 6 (data not
shown). As expected, Sox3 expression was not detected in the
mutant samples (Fig. 1E). Together these data indicate that Sox3 is
rapidly upregulated during N2B27 neurodifferentiation and that
loss of Sox3 does not overtly affect NP induction across this
timeframe, probably due to functional redundancy with other
SOXB1 proteins.
Identification of SOX3 Target Genes
To identify putative SOX3 target genes, we compared the
global gene expression profile of Day 4 NP cell cultures derived
from Sox3 null cells and a control cell line containing a conditional
Sox3 allele [17]. Microarray analysis was performed in quadrupli-
cate using 4 biological replicates from two independent experi-
ments. A total of 19 genes had significantly (p#0.05) altered
expression with a fold change of 1.4 or more, as determined by
batch corrected two-way ANOVA analysis (Table 1). Fifteen and 4
genes were upregulated and downregulated, respectively. Sox3
provided an internal control for this experiment and, as expected,
this gene was significantly downregulated in the Sox3 null samples.
Further validation of a subset of the misregulated genes was
conducted using qRT-PCR on independent biological samples.
Dbx1 (p = 0.049) and Fezf2 (p = 0.0228) showed significant down
regulation in mutant cells (Fig. 2A). Significantly elevated
expression of Efnb3 (p = 0.0229), Cspg5 (p = 0.0251), Fam174b
(p = 0.0065), Ddr2 (p = 0.0386) and Slit1 (p = 0.0456) was also
confirmed in the independent samples. These data identifies a
number of potential SOX3 targets in cultured NP cells.
Table 1. Table of significantly regulated genes with a fold change equal to or greater than 1.4 in Day 4 N2B27 differentiated ES
cells.
Gene Symbol RefSeq stepup p-value Fold-Change Fold-Change (Description)
Independently
Validated
Sox3 NM_009237 0.01 24.10 KO down vs WT Yes
Cspg5 NM_001166273 0.02 1.49 KO up vs WT Yes
Ddr2 NM_022563 0.02 1.83 KO up vs WT Yes
Slit1 NM_015748 0.04 1.87 KO up vs WT Yes
Tagln3 NM_019754 0.04 1.54 KO up vs WT
1200009O22Rik NM_025817 0.04 1.41 KO up vs WT
Tmem163 NM_028135 0.04 21.45 KO down vs WT No
Slc44a5 NM_001081263 0.05 1.44 KO up vs WT No
Fezf2 NM_080433 0.05 21.61 KO down vs WT Yes
Fam174b NM_001162532 0.05 1.64 KO up vs WT Yes
Fgfr3 NM_008010 0.05 1.65 KO up vs WT
Flrt2 NM_201518 0.05 1.46 KO up vs WT
Dbx1 NM_001005232 0.05 22.35 KO down vs WT Yes
Gpr56 NM_018882 0.05 1.56 KO up vs WT
Efnb3 NM_007911 0.05 1.59 KO up vs WT Yes
Nexn NM_199465 0.05 1.72 KO up vs WT
Ctgf NM_010217 0.05 1.45 KO up vs WT
Cp NM_001042611 0.05 2.04 KO up vs WT No
Ednrb NM_007904 0.05 1.53 KO up vs WT No
doi:10.1371/journal.pone.0095356.t001
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Figure 2. Validation of putative Sox3 targets. A: qRT-PCR validation of gene expression levels of down regulated genes, Dbx1 and Fezf2 (n = 3).
B: qRT-PCR validation of gene expression levels of up regulated genes Ddr2, Slit1, Cspg5, Efnb3 and Fam174b (n = 3). C: Percentage of significantly
regulated genes with SOX3 binding sites, as closest gene. RQ: relative quantification normalised to b-actin.
doi:10.1371/journal.pone.0095356.g002
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Figure 3. Validation of putative Sox3 targets in vivo. A: Dbx1 gene expression within whole 9.5 dpc embryos. B: Dbx1 gene expression within
10.5 dpc dissected heads. C: qRT-PCR analysis of mRNA levels of Sox1, Sox2, Slit1 and Fezf2 showing no significant difference. RQ: relative
quantification normalised to b-actin.
doi:10.1371/journal.pone.0095356.g003
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Correlation between SOX3 Binding Sites and Sox3
Targets
Differentially expressed genes in Sox3 null NPs potentially
represent genes that are direct SOX3 targets. To investigate this
possibility, we examined the differentially expressed genes for
SOX3 binding sites using a previously published SOX3 ChIP-seq
data set generated using a comparable NP differentiation system
[4]. A significant enrichment of SOX3 binding sites was present in
genes with altered expression in Sox3 null NP cells. Over 83% of
the differentially expressed genes (Table 1) have at proximal
(closest gene) SOX3 binding site (Fig. 2C). In contrast, SOX3
binding sites were detected in only 25% of 20 randomly selected
genes that do not display altered expression in Sox3 null NPs. The
enrichment of SOX3 binding sites near genes with significantly
altered expression genes suggests that many of these genes are
direct targets of SOX3.
In vivo Validation of SOX3 Targets
Next, we investigated whether the differentially-expressed NP
culture genes were affected by the loss of Sox3 in vivo. This
analysis was performed using 9.5 dpc embryos (somite stages 12–
15) as embryos at this stage of development have an abundance of
NP cells and a paucity of differentiating neurons. In addition, like
Day 4 NP cell cultures, Sox1 and Sox2 expression in not
significantly altered in Sox3 null embryos at this stage (Fig. 3C).
qRT-PCR analysis of Slit1 and Fezf2 showed no significant
difference in expression between WT and Sox3 null embryos at this
developmental time point (Fig. 3C). In contrast, Dbx1 expression
was significantly lower in Sox3 null embryos at 9.5 dpc (Fig. 3A),
consistent with its downregulation in Sox3 null NP cells. A
significant reduction in Dbx1 expression was also evident in
10.5 dpc embryonic heads (Fig. 3).
To determine the impact of Sox3 loss-of-function on DBX1
expression at the cellular level, we compared the number of
DBX1+ cells in Day 4 NP cultures using immunohistochemistry
(Figure 4 A). DBX1+ cells were readily identified in control
cultures and were located in a subpopulation of SOX3+ cells
located at the periphery of cell clusters. In contrast, the number of
DBX1+ cells was significantly and dramatically reduced in SOX3
KO cultures (Figure 4B). To determine whether there is a similar
reduction in DBX1+ cells in Sox3 mutant embryos, we compared
DBX1 expression in 9.5 dpc transverse sections through the trunk
region. Again, a clear reduction in the number of DBX1+ cells
within the spinal cord of Sox3 null mice was evident (Fig. 4C).
Together these data suggest that Dbx1 is regulated by SOX3 in vivo
and that other SoxB1 factors cannot fully compensate for the loss
of SOX3.
SOX3 Binds to the Dbx1 Locus In vivo
To investigate whether Dbx1 is directly targeted by SOX3 in
Day 4 NP cells, we performed ChIP-PCR on five SOX3 binding
sites located in or near the Dbx1 locus that were previously
Figure 4. DBX1 levels within neural progenitor cells and the developing spinal cord. A: DBX1 expression at day 4 of N2B27 differentiation.
B: Number of DBX1+ cells per field of view at day 4 of N2B27 differentiation. C: DBX1 expression within the developing 9.5 dpc spinal cord of wild
type and Sox3 null mice.
doi:10.1371/journal.pone.0095356.g004
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identified by ChIP-seq analysis ([4]; Fig. 5A). Significant (p#0.05)
enrichment of all five sites was detected by SOX3 ChIP-PCR,
when compared to the IgG isotype control (Fig. 5B). To determine
if SOX3 bound these sites in vivo, we analysed SOX3 binding to
one of the most enriched sites (Intronic site 2) using chromatin
extracted from 10.5 dpc embryonic heads. Significant enrichment
(p#0.001) of this SOX3 binding this site was observed in
comparison to the IgG negative control (Fig. 5C). Together, these
data indicate that Dbx1 is a direct target of SOX3 in vivo.
Discussion
Despite the widespread expression of Sox3 in progenitor cells
throughout the neuroaxis, the CNS phenotypes of mice and
humans with Sox3 mutations are relatively mild. It is generally
believed that other SOXB1 proteins (SOX1 and SOX2) can
function redundantly with SOX3 to ‘‘rescue’’ the SOX3
deficiency. However, the lack of a complete phenotypic rescue
suggests that, at least in some NP cells, the level of SOXB1 protein
may be important for neurodevelopment. Alternatively, each of
the SOXB1 factors could bind preferentially to a unique subset of
SOXB1 targets. As a result, target gene expression resulting from
the loss of a single SOXB1 gene would only be partially rescued by
the other two SOXB1 factors. To explore this issue in more detail,
we attempted to identify genes that were sensitive to the loss of
SOX3 in NP cells. To do this we used a previously targeted Sox3
null ES cell line in which the single SOX3 exon was replaced with
GFP [17]. N2B27-induced generation of conditionally targeted
and Sox3 null NP cells resulted in rapid upregulation of Sox3/GFP
at the mRNA and protein level. The NP markers Sox1 and Pax6
were also rapidly induced and showed comparable kinetics in the
control and mutant cultures. In addition, expression of Sox2 was
comparable between the two populations. Notably, no overt
defects in the morphology or global gene expression (see below)
were identified in Sox3 null NP cells. This is likely due to the
expression of Sox1 and Sox2 in N2B27-induced NP cells and is
consistent with the mild CNS phenotype of Sox3 null embryos.
To maximise the likelihood of identifying genes that are directly
regulated by SOX3, we performed gene expression profiling at
Day 4, the earliest time point at which high levels of Sox3 were
expressed in the majority of NP cells. Of over 24,000 genes
assayed by microarray, only 19 had significantly different
expression levels .1.4-fold at Day 4. Expression differences (when
tested by qRT-PCR) were validated on independent samples for a
majority of the targets, thereby confirming the authenticity of the
microarray data. However, not all differentially expressed genes
validated on independent samples (Tmem163, Ednrb, and Slc44a5,
data not shown). The relatively small number of differentially
expressed genes is interesting to consider in the context of a
recently-published ChIP-seq analysis of a similar NP cell type,
which showed that SOX3 binds at thousands of genomic sites,
many of which are likely to have regulatory functions [4].
Preliminary ChIP-seq analysis from our laboratory also indicates
that SOX3 binds many of these sites in Day 4 N2B27-induced NP
cells (D.M. and P.T. unpublished data). The most parsimonious
explanation for the small number of differentially expressed genes
is that SOX1 and/or SOX2 (both of which are expressed by Day
4 NP cells) can bind and functionally compensate for loss of
Figure 5. SOX3 binding sites surrounding Dbx1. A: Schematic diagram of previously published SOX3 binding sites (not to scale). B: In vitro ChIP
validation of the five surrounding SOX3 binding sites (n = 3). C: In vivo ChIP validation of SOX3 binding to intronic site 2 in 10.5 dpc dissected heads
(n = 3). All ChIP enrichment is relative to input and normalised to IgG IP.
doi:10.1371/journal.pone.0095356.g005
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SOX3. Consistent with this hypothesis, almost all SOX2 binding
sites in NPs also bind SOX3 [4]. However, while SOXB1
redundancy provides an explanation for the unaltered expression
of most genes associated with SOX3 binding sites, it also suggests
that differentially expressed genes cannot be fully compensated by
SOX1 and SOX2. Given the HMG domain of SOXB1 proteins is
not identical, it is possible that they have subtly different
preferences for sequence-specific binding in vivo, as has been
suggested by in vitro DNA binding experiments [18]. In addition,
amino acid differences within the HMG box (or outside of it) may
influence interactions with DNA binding partners such as the
POU-class transcription factors [19,20]. Regardless of the
mechanism, it is important to note that the differentially expressed
genes are highly enriched for SOX3 binding sites (over randomly
selected genes without significantly different expression levels),
supporting the idea that they represent direct SOX3 targets. As a
number of these putative direct target genes are upregulated, it
appears that that SOX3 could function as a repressor in NP cells
[21] in addition to its more established role as an activator [2].
Interestingly, many of the genes identified by the microarray
analysis have established roles in neurodevelopment. For example,
Cspg5 has been associated with intellectual disability disorders [22],
and ectopic Slit1 expression has been published in mice with
abnormal corpus callosum development [23]. Intellectual disability
is present in a subset of individuals with SOX3 mutations [7], while
Sox3 null mice have abnormal corpus callosum development [5],
thereby providing a link between these putative targets and
processes with a functional requirement for SOX3.
Another putative SOX3 target was the downregulated tran-
scription factor gene Fezf2. Fezf2 has been shown to be important
for the early development of the posterior hypothalamus/thalamus
in zebrafish and mouse [24,25]. Fezf2 expression has been
previously published to be downstream of the SOXC group genes
Sox4 and Sox11, double deletion of which leads to a loss of Fezf2
expression. Regulation of Fezf2 by SOX4/11 gene is mediated by
a cis acting enhancer binding site which, interestingly, was also
identified as a SOX3 binding site in NP cells by ChIP-seq and
independently within our lab (data not shown; [4,26]). These data
suggest that, in addition to acting as a pioneer factor [4], Sox3 may
directly regulate Fezf2 expression in NP cells.
Dbx1 is a Direct SOX3 Target In vivo
To investigate whether NP targets were dysregulated in vivo, we
compared their expression by qRT-PCR using whole 9.5 dpc
embryos. Of the seven putative targets analysed (Fig. 3C, data not
shown), only one (Dbx1) had significantly different expression that
matched the genome-wide expression profiling analysis. The lack
of in vivo validation for other targets may reflect a phenotypic or
stage-specific difference in the NP cells induced by N2B27
differentiation compared with their 9.5 dpc embryonic counter-
parts. Consistent with this idea, expression analysis of Sox3 targets
in Day 6 NP cells revealed that many genes no longer had
significantly different expression levels or had greatly reduced
expression fold changes (Fig. S1). Dbx1 expression, however, was
reduced in whole 9.5 dpc embryos lacking Sox3. In addition,
DBX1+ cells were not detected in the spinal cord of Sox3 null
embryos at 9.5 dpc and were massively reduced in Day 4 null NP
cells. Further, SOX3 bound to evolutionarily conserved elements
at the Dbx1 locus in cultured NP cell and embryos. Together these
data indicate that Dbx1 is directly activated by SOX3 in NP cells.
Dbx1 encodes a homeoprotein that is transiently expressed in Vo
interneuron precursors and required for Vo interneuron differen-
tiation [27]. The lack of DBX1 expression in the spinal cord of
Sox3 null embryos is the first clear evidence that there is a
phenotype within the developing spinal cord of Sox3 null mice and
raises the possibility that generation of Vo interneurons is
abnormal in Sox3 mutants [5]. The significantly reduced DBX1
expression in Sox3 null spinal cord NPs also provides some
molecular insights into SOXB1 functional redundancy. Given that
the spinal cord NPs have virtually identical SOXB1 expression
[2,14], it appears that SOX1 and SOX2 are unable to substitute
for SOX3 in the context of Dbx1 regulation. As discussed above,
this might reflect preferential binding of SOX3 at the Dbx1 locus.
Alternatively, Dbx1 expression could be sensitive to the overall
dosage of SOXB1 protein. At least two experimental approaches
could be used to test these possibilities. Firstly, it would be
interesting to examine Dbx1 expression in Sox1 and Sox2 single
gene KO NP cells ie. under conditions where the overall SOXB1
dosage is lower but SOX3 is present. Secondly, a targeted gene
replacement strategy (eg. replacing Sox3 with Sox2) could be used
to generate NP cells that have an equivalent SOXB1 dosage but
which lack SOX3. In addition to the spinal cord, we identified a
reduction in Dbx1 expression in the head of 10.5 dpc Sox3 null
embryos. However, we were unable to determine whether this
reflected a lack of Dbx1 expression in a specific region or general
reduction in the Dbx1 expression level (data not shown).
A recent report by Oosterveen et al also indicated that Dbx1 is a
direct target of Sox3 [28]. However, the SOX3 binding sites
reported by Oosterveen et al are contained within a putative cis-
regulatory module (CRM) that does not overlap with the SOX3
binding sites identified in this study. The Oosterveen et al data
raises the possibility that (the lack of) SOX3 binding at the CRM
sites may contribute to the reduction of Dbx1 expression in Sox3
null NPs. The data also suggest that the regulation of Dbx1 by
SOX3 is complex and subtle differences between early or later
expression or spinal cord/brain expression might be regulated any
number of these sites. Further studies are needed to address this
issue. Given the increasing ease with which the genome can be
manipulated [29], it would be interesting to perform systematic
mutagenesis of all known SOXB1 sites at the Dbx1 locus and assess
their impact on Dbx1 expression in vitro and in vivo.
Supporting Information
Figure S1 Expression of putative Sox3 targets at day 6 of
neural progenitor differentiation. A: Putative targets Dbx1
and Slit1 relative gene expression levels by qRT-PCR at day 6 of
N2B27 differentiation, (n = 3 normalised to day 4). B: Putative
targets Cp, Fezf2 and Efnb3 showing reduced and/or insignificant
fold change at day 6 of N2B27 differentiation (n = 3, normalised to
day 4). RQ: relative quantification normalised to b-actin.
(TIF)
Acknowledgments
We thank Dr. Alessandra Pierani and Prof. Robin Lovell-Badge for
provision of the DBX1 antibody and Sox3 mutant mice, respectively. PT is
a Pfizer Australia Research Fellow.
Author Contributions
Conceived and designed the experiments: NR DM PT. Performed the
experiments: NR DM. Analyzed the data: NR DM PT. Contributed
reagents/materials/analysis tools: NR DM PT. Wrote the paper: NR PT.
Dbx1 Is a Direct Target of SOX3 in the Spinal Cord
PLOS ONE | www.plosone.org 8 April 2014 | Volume 9 | Issue 4 | e95356
References
1. Lefebvre V, Dumitriu B, Penzo-Mendez A, Han Y, Pallavi B (2007) Control of
cell fate and differentiation by Sry-related high-mobility-group box (Sox)
transcription factors. Int J Biochem Cell Biol 39: 2195–2214.
2. Bylund M, Andersson E, Novitch BG, Muhr J (2003) Vertebrate neurogenesis is
counteracted by Sox1-3 activity. Nat Neurosci 6: 1162–1168.
3. Rogers N, Cheah PS, Szarek E, Banerjee K, Schwartz J, et al. (2013) Expression
of the murine transcription factor SOX3 during embryonic and adult
neurogenesis. Gene Expr Patterns 13: 240–248.
4. Bergsland M, Ramskold D, Zaouter C, Klum S, Sandberg R, et al. (2011)
Sequentially acting Sox transcription factors in neural lineage development.
Genes Dev 25: 2453–2464.
5. Rizzoti K, Brunelli S, Carmignac D, Thomas PQ, Robinson IC, et al. (2004)
SOX3 is required during the formation of the hypothalamo-pituitary axis. Nat
Genet 36: 247–255.
6. Rizzoti K, Lovell-Badge R (2007) SOX3 activity during pharyngeal segmen-
tation is required for craniofacial morphogenesis. Development 134: 3437–3448.
7. Laumonnier F, Ronce N, Hamel BC, Thomas P, Lespinasse J, et al. (2002)
Transcription factor SOX3 is involved in X-linked mental retardation with
growth hormone deficiency. Am J Hum Genet 71: 1450–1455.
8. Woods KS, Cundall M, Turton J, Rizotti K, Mehta A, et al. (2005) Over- and
underdosage of SOX3 is associated with infundibular hypoplasia and
hypopituitarism. Am J Hum Genet 76: 833–849.
9. Nishiguchi S, Wood H, Kondoh H, Lovell-Badge R, Episkopou V (1998) Sox1
directly regulates the gamma-crystallin genes and is essential for lens
development in mice. Genes Dev 12: 776–781.
10. Ekonomou A, Kazanis I, Malas S, Wood H, Alifragis P, et al. (2005) Neuronal
migration and ventral subtype identity in the telencephalon depend on SOX1.
PLoS Biol 3: e186.
11. Malas S, Postlethwaite M, Ekonomou A, Whalley B, Nishiguchi S, et al. (2003)
Sox1-deficient mice suffer from epilepsy associated with abnormal ventral
forebrain development and olfactory cortex hyperexcitability. Neuroscience 119:
421–432.
12. Ferri AL, Cavallaro M, Braida D, Di Cristofano A, Canta A, et al. (2004) Sox2
deficiency causes neurodegeneration and impaired neurogenesis in the adult
mouse brain. Development 131: 3805–3819.
13. Favaro R, Valotta M, Ferri AL, Latorre E, Mariani J, et al. (2009) Hippocampal
development and neural stem cell maintenance require Sox2-dependent
regulation of Shh. Nat Neurosci 12: 1248–1256.
14. Wood HB, Episkopou V (1999) Comparative expression of the mouse Sox1,
Sox2 and Sox3 genes from pre-gastrulation to early somite stages. Mech Dev 86:
197–201.
15. Uchikawa M, Yoshida M, Iwafuchi-Doi M, Matsuda K, Ishida Y, et al. (2011)
B1 and B2 Sox gene expression during neural plate development in chicken and
mouse embryos: universal versus species-dependent features. Dev Growth Differ
53: 761–771.
16. Ying QL, Stavridis M, Griffiths D, Li M, Smith A (2003) Conversion of
embryonic stem cells into neuroectodermal precursors in adherent monoculture.
Nat Biotechnol 21: 183–186.
17. Hughes J, Piltz S, Rogers N, McAninch D, Rowley L, et al. (2013) Mechanistic
insight into the pathology of polyalanine expansion disorders revealed by a
mouse model for X linked hypopituitarism. PLoS Genet 9: e1003290.
18. Collignon J, Sockanathan S, Hacker A, Cohen-Tannoudji M, Norris D, et al.
(1996) A comparison of the properties of Sox-3 with Sry and two related genes,
Sox-1 and Sox-2. Development 122: 509–520.
19. Kamachi Y, Uchikawa M, Kondoh H (2000) Pairing SOX off: with partners in
the regulation of embryonic development. Trends Genet 16: 182–187.
20. Kondoh H, Kamachi Y (2010) SOX-partner code for cell specification:
Regulatory target selection and underlying molecular mechanisms. Int J Biochem
Cell Biol 42: 391–399.
21. Acloque H, Ocana OH, Matheu A, Rizzoti K, Wise C, et al. (2011) Reciprocal
repression between Sox3 and snail transcription factors defines embryonic
territories at gastrulation. Dev Cell 21: 546–558.
22. Zhang C, Mejia LA, Huang J, Valnegri P, Bennett EJ, et al. (2013) The X-linked
intellectual disability protein PHF6 associates with the PAF1 complex and
regulates neuronal migration in the mammalian brain. Neuron 78: 986–993.
23. Amaniti EM, Hasenpusch-Theil K, Li Z, Magnani D, Kessaris N, et al. (2013)
Gli3 is required in Emx1+ progenitors for the development of the corpus
callosum. Dev Biol 376: 113–124.
24. Hirata T, Nakazawa M, Muraoka O, Nakayama R, Suda Y, et al. (2006) Zinc-
finger genes Fez and Fez-like function in the establishment of diencephalon
subdivisions. Development 133: 3993–4004.
25. Wolf A, Ryu S (2013) Specification of posterior hypothalamic neurons requires
coordinated activities of Fezf2, Otp, Sim1a and Foxb1.2. Development 140:
1762–1773.
26. Shim S, Kwan KY, Li M, Lefebvre V, Sestan N (2012) Cis-regulatory control of
corticospinal system development and evolution. Nature 486: 74–79.
27. Pierani A, Moran-Rivard L, Sunshine MJ, Littman DR, Goulding M, et al.
(2001) Control of interneuron fate in the developing spinal cord by the
progenitor homeodomain protein Dbx1. Neuron 29: 367–384.
28. Oosterveen T, Kurdija S, Enstero M, Uhde CW, Bergsland M, et al. (2013)
SoxB1-driven transcriptional network underlies neural-specific interpretation of
morphogen signals. Proc Natl Acad Sci U S A 110: 7330–7335.
29. Wang H, Yang H, Shivalila CS, Dawlaty MM, Cheng AW, et al. (2013) One-
step generation of mice carrying mutations in multiple genes by CRISPR/Cas-
mediated genome engineering. Cell 153: 910–918.
Dbx1 Is a Direct Target of SOX3 in the Spinal Cord
PLOS ONE | www.plosone.org 9 April 2014 | Volume 9 | Issue 4 | e95356
